Amoy Diagnostics

Amoy Diagnostics, Amgen Partner on Lung Cancer CDx Development for Lumakras in Japan

Amoy Diagnostics will develop its PCR-based panel as a companion diagnostic in Japan to screen NSCLC patients for Amgen's KRAS G12C inhibitor.

Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko

The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.

AmoyDx PCR Panel Receives Japanese Approval as CDx for Non-Small Cell Lung Cancer Therapies

The Japanese MHLW approved the real-time PCR-based test as a CDx to detect four driver genes for nine associated NSCLC targeted therapies.

In Brief This Week: Grail, Illumina, Veracyte, Aspira Women's Health, and More

News items for the in vitro diagnostics industry for the week of March 15, 2021.

AmoyDx, AstraZeneca Strike Ovarian Cancer Companion Diagnostic Alliance

The companies have worked together on a number of other cancer-related projects, including a companion diagnostic for the ovarian cancer treatment olaparib.

Dec 23, 2020